Dr Reddy's Laboratories Ltd (NYSE:RDY)
| 67.86 Delayed Data As of Nov 28 |  +0.16 / +0.24%Today’s Change | 51.11 Today|||52-Week Range 73.17 | +31.13% Year-to-Date |
Latest RDY News | Press Releases
| Why Doctor Reddy's (RDY) is a Top Growth Stock for the Long-Term Nov 24 / Zacks.com - Paid Partner Content | Why Doctor Reddy's (RDY) is a Top Momentum Stock for the Long-Term Nov 20 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 67.70 |
| Today’s open | 67.87 |
| Day’s range | 67.76 - 68.20 |
| Volume | 211,063 |
| Average volume (3 months) | 277,519 |
| Market cap | $11.4B |
Data as of 3:59pm ET, 11/28/2023
Growth & Valuation
| Earnings growth (last year) | +77.12% |
| Earnings growth (this year) | -5.82% |
| Earnings growth (next 5 years) | +14.80% |
| Revenue growth (last year) | +6.33% |
| P/E ratio | 18.5 |
| Price/Sales | 3.10 |
| Price/Book | 4.04 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| VTRSViatris Inc | -0.21 | -2.19% |
| ---- | ||
| UTHRUnited Therapeutics ... | -0.66 | -0.29% |
| ---- |
Data as of 4:00pm ET, 11/28/2023
Financials
| Next reporting date | January 26, 2024 |
| EPS forecast (this quarter) | $0.68 |
| Annual revenue (last year) | $3.1B |
| Annual profit (last year) | $560.8M |
| Net profit margin | 18.33% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Hyderabad, Telangana |
Forecasts
